These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 807637)

  • 21. Antibody responses to antigenic determinants of influenza virus hemagglutinin. I. Thymus dependence of antibody formation and thymus independence of immunological memory.
    Virelizier JL; Postlethwaite R; Schild GC; Allison AC
    J Exp Med; 1974 Dec; 140(6):1559-70. PubMed ID: 4139233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
    J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
    Bot A; Casares S; Bot S; von Boehmer H; Bona C
    J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of protective immunity against influenza virus infection in mice without antibodies.
    Epstein SL; Lo CY; Misplon JA; Bennink JR
    J Immunol; 1998 Jan; 160(1):322-7. PubMed ID: 9551987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes.
    Virelizier JL; Allison AC; Schild GC
    J Exp Med; 1974 Dec; 140(6):1571-8. PubMed ID: 4139234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of total or partial T lymphocyte depletion on susceptibility to influenza virus infection and development of antiviral immunity in lethally irradiated mice reconstituted with immune syngeneic bone marrow grafts.
    Mumcuoglu M; Zakay-Rones Z; Weiss L; Slavin S
    Bone Marrow Transplant; 1991 Mar; 7(3):217-20. PubMed ID: 1647828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response.
    Kuwano K; Scott M; Young JF; Ennis FA
    J Immunol; 1988 Feb; 140(4):1264-8. PubMed ID: 2449498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recovery from a viral respiratory tract infection. IV. Specificity of protection by cytotoxic T lymphocytes.
    Wells MA; Daniel S; Djeu JY; Kiley SC; Ennis FA
    J Immunol; 1983 Jun; 130(6):2908-14. PubMed ID: 6189904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Passive transfer of local immunity to influenza virus infection by IgA antibody.
    Renegar KB; Small PA
    J Immunol; 1991 Mar; 146(6):1972-8. PubMed ID: 2005388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the anti-influenza activities of antibodies and immune system cells administered intranasally to syngeneic mice.
    Maiorova LP; Smorodintsev AA
    Acta Virol; 1982 Sep; 26(5):353-61. PubMed ID: 6128903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection.
    Tite JP; Hughes-Jenkins C; O'Callaghan D; Dougan G; Russell SM; Gao XM; Liew FY
    Immunology; 1990 Oct; 71(2):202-7. PubMed ID: 2172156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide.
    Kostolanský F; Mucha V; Slováková R; Varecková E
    Acta Virol; 2002; 46(4):229-36. PubMed ID: 12693859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The senescence-accelerated mouse shows aging-related defects in cellular but not humoral immunity against influenza virus infection.
    Dong L; Mori I; Hossain MJ; Kimura Y
    J Infect Dis; 2000 Aug; 182(2):391-6. PubMed ID: 10915067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.
    Tamura S; Kurata T
    Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.